Drug developer Absci slides after $50 million stock offering

** Shares of AI-based drug developer Absci ABSI down 14.8% at $2.99 premarket

** ABSI late Thursday sold 16.67 million shares at $3 apiece for gross proceeds of $50 million

** Stock offering priced at 14.5% discount to last close

** Proceeds will be used to advance its drug creation platform and other purposes

** Morgan Stanley, J.P.Morgan, Jefferies and TD Cowen were joint book-running managers for the offering

** ABSI had 127.54 million outstanding shares, as of March 31, according to offering prospectus

** All 9 brokerages covering the stock rate "buy" or higher; median PT $9 - data compiled by LSEG

** As of last close, ABSI shares up 34% YTD

​